ELA vs NBIX · P/E 21, rev $155.2M vs P/E 45, rev $1.77B
Envela Corp (ELA) versus Neurocrine Biosciences Inc (NBIX) — a side-by-side from cached financials, not a winner call.
Envela Corp (ELA) is a luxury goods company listed on US.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
Latest reported ELA revenue for 2026-06-30 was $155.2M. Net income was $13.0M. Revenue was up 57.7% from 2026-03-31 to 2026-06-30. ELA currently screens at market cap $158.1M and trailing P/E 21.0.
Latest reported NBIX revenue for 2026-06-30 was $1.77B. Net income was $342.3M. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
ELA currently screens at market cap $158.1M and trailing P/E 21.0. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
Not investment advice. Open the ELA and NBIX stock pages for the full models.
Not investment advice.